• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC - GALWAY SYNERGY¿; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC - GALWAY SYNERGY¿; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number UNK776
Device Problem Occlusion Within Device (1423)
Patient Problem Thrombosis (2100)
Event Type  Injury  
Manufacturer Narrative
Nakano, shinsuke, et.Al., comparison of early healing after three types of drug-eluting stent implantation using optical coherence tomography (zience/promus vs ultimaster vs synergy), oe-38, oral presentation, the 31st annual scientific meeting of the japanese circulation society.Device is combination product.Device evaluated by mfr: the complaint device was not received for analysis.The investigation conclusion is anticipated procedural complication as the event is due to a known physiological effect of the procedure noted within the directions for use, and/or device labeling.(b)(4).
 
Event Description
It was reported via journal article that stent thrombosis occurred.Early vessel healing may attribute for shortening the duration of dual anti-platelet ther­apy (dapt).Optical coherence tomogra­phy (oct) was performed 3 to 4 months after drug-eluting stent (des) implantation.Strut coverage, neointimal thickness, lumen and stent area, and intra-stent thrombus were evaluated.Fourteen non-bsc permanent-polymer everolimus-eluting stent, thirteen non-bsc biodegradable-polymer sirolimus-eluting stents, and nineteen synergy¿ biodegradable-polymer everolim.Us-eluting stents were analyzed.The average duration after implantation was 109.2 days.The synergy¿ % covered strut was 93%, the average neointimal thickness was thickest in synergy¿ and the frequency of synergy¿ in-stent thrombus was 22.2%.The conclusion reached was that the extent of early vessel heal­ing may be different between 2nd and 3rd generation des which may have an impact on dap duration.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY¿
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BOSTON SCIENTIFIC - GALWAY
Manufacturer (Section G)
BOSTON SCIENTIFIC - GALWAY
Manufacturer Contact
sonali arangil
one scimed place
maple grove, MN 55311
7634941700
MDR Report Key7475337
MDR Text Key106972008
Report Number2134265-2018-03353
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
PMA/PMN Number
SIMILAR
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 04/02/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK776
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 04/02/2018
Initial Date FDA Received05/01/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-